Used in combination with trifluridine for the treatment of metastatic colorectal cancer. The compound enhances the bioavailability of trifluridine by inhibiting its degradation in the body, allowing higher concentrations to remain active in the bloodstream. This combination therapy is particularly indicated for patients who have exhausted other treatment options, including chemotherapy regimens involving fluoropyrimidines, oxaliplatin, and irinotecan. It is administered orally and has shown efficacy in prolonging survival in refractory cases.